



Contacts: Meg McGilley  
Chief Financial Officer  
(858) 480-0402

Rob Whetstone  
PondelWilkinson Inc.  
(310) 279-5963

## Somaxon Pharmaceuticals to Report 2007 Fourth Quarter and Full Year Financial Results and Host Conference Call on March 11, 2008

**SAN DIEGO, CA – March 6, 2008** – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that it will release its 2007 fourth quarter and full year financial results after the market closes on Tuesday March 11, 2008. Somaxon management will host a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to review the financial results and answer questions.

The conference call will be available to interested parties through a live audio Internet broadcast at <http://investors.somaxon.com/events.cfm>. The call will also be archived and accessible for one year. Alternatively, callers may participate in the conference call by dialing (866) 249-5225 (domestic) or (303) 262-2194 (international). A telephonic replay will be available for approximately one week following the conclusion of the call by dialing (800) 405-2236 (domestic) or (303) 590-3000 (international), and entering passcode 11109892.

### **About Somaxon Pharmaceuticals, Inc.**

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon has completed four successful Phase 3 clinical trials for its lead product candidate, SILENOR™ (doxepin HCl) for the treatment of insomnia.

For more information, please visit the company's web site at [www.somaxon.com](http://www.somaxon.com).

###